RxDoctor Payments Data

Joel David, DO

Internal Medicine · South Euclid, OHNPI 1942560222

Payments from drug & device makers

$4,136in general payments, 2019–2025

Across 250 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$553
  • AbbVie$422
  • Lilly USA, LLC$302
  • Amgen$282
  • GSK$223
  • Novo Nordisk$219
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,136 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$61,169
Medicare patients
230
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$144,047
TrulicityDulaglutide115$135,207
OzempicSemaglutide103$112,088
EliquisApixaban117$102,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$39,435
MounjaroTirzepatide34$37,752
FarxigaDapagliflozin Propanediol37$34,383
JanuviaSitagliptin Phosphate37$32,730
XareltoRivaroxaban25$26,317
Soliqua 100-33Insulin Glargine/Lixisenatide26$20,271
CreonLipase/Protease/Amylase11$11,202
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,263
Breo ElliptaFluticasone/Vilanterol25$8,933
Repatha SureclickEvolocumab11$7,990
SymbicortBudesonide/Formoterol Fumarate19$6,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$302$172,959149 claims
Boehringer IngelheimJardiance$124$144,047108 claims
Novo NordiskOzempic$219$112,088103 claims
PfizerEliquis$138$102,657117 claims
GSKTrelegy Ellipta, Breo Ellipta$223$48,36970 claims
AstraZenecaFarxiga, Symbicort$553$41,28156 claims
MerckJanuvia$190$32,73037 claims
Johnson & JohnsonXarelto$61$26,31725 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$19$20,27126 claims
AbbVieCreon$422$11,20211 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$37$2,456268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in South Euclid

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →